Coagulation factor Vlll (FVIII) is a cofactor in the intrinsic pathway of blood coagulation for which deficiency results in the bleeding disorder hemophilia A. FVlll contains a domain structure of A I -A2-B-A3-C1 -C2 of which the B domain is dispensable for procoagulant activity in vitro. In this report, we compare the properties of B-domain-deleted FVlll (residues 760 through 1639, designated LA-VIII) to wildtype recombinant FVIII. In transfected Chinese hamster ovary (CHO) cells, LA-VIII was expressed at a 10-to 20-fold greater level compared with wildtype FVIII. The specific activity of purified LA-VIII was indistinguishable from wildtype recombinant FVlll and both exhibited similarthrombin activation coefficients. Wildtype recombinant-derived FVlll and LA-VIII also displayed similar timecourses of thrombin activation and heavy chain cleavage. However, compared with wildtype recombinant-derived FVIII, the light chain of LA-VIII was cleaved fivefold more rapidly by thrombin. Ad-ACTOR VI11 (FVIII) functions in the intrinsic pathway The heavy chain is composed of domains Al-A2-B while the light chain is composed of domains A3-Cl-C2. The large B domain is encoded by a single large exon4 and has no detectable homology to any other known genes. The B domain is extensively glycosylated on asparagine, serine, and threonine residues.536 In addition to the primary amino acid sequence, the isolation of the FVIII gene provided the ability to express FVIIl in transfected mammalian cells to study its biosynthesis and pro~essing.~ It was also possible to construct specific mutations within FVIII to study structural requirements for FVIII function.'-' Initial studies showed that deletion of the B domain resulted in a functional molecule as tested by in vitro assays and was expressed more efficiently compared with wildtype FVIII.7,10-'2 Hemophilia A is treated by frequent administration of FVIII preparations derived from pooled human plasma. In the past this therapeutic regimen had associated complications of blood-borne infectious pathogens. Recently, the availability of monoclonal antibody (MoAb) affinity-purified plasma FVIII preparations has significantly reduced risks associated with plasma-borne infectious agents.13 However, treatment is generally limited on demand basis because of the limited availability and high cost associated with highly purified plasma-derived FVIII. This may be alleviated in the near future by the availability of recombinantderived human FVIII.'4,'5 However, the present manufacturing process for FVIII has limitations because of the inefficiencies of producing, purifying, and characterizing this large heterogeneous dition of purified von Willebrand factor (vWF) did not alter the kinetics of thrombin cleavage or activation of either wildtype recombinant-derived FVlll or LA-VIII. The immunogenicity of LA-VIII was compared with wildtype FVlll in a novel model of neonatal tolerance induction in mice. The results did not detect any immunologic differences between wildtype FVlll and LA-VIII, suggesting that LA-VIII does not contain significant new epitopes that are absent in wildtype FVIII. LA-VIII was tolerated well on infusion into FVIII-deficient dogs and was able to correct the cuticle bleeding time similar to wildtype recombinant factor VIII. In vivo, LA-VIII was bound to canine vWF and exhibited a half-life similar to wildtype recombinant FVIII. These studies support that B-domain-deleted FVlll may be efficacious in treatment of hemophilia A in humans. glycoprotein. For these reasons it should be advantageous to produce a more efficiently expressed molecule that has reduced heterogeneity to reduce the cost to provide prophylactic therapy for hemophilia A. Here we describe the production and characterization of a B-domain-deleted form of FVIII and show that it has biochemical, immunologic, and in vivo functional properties very similar to wildtype recombinantderived human FVIII.
FVlll (residues 760 through 1639, designated LA-VIII) to wildtype recombinant FVIII. In transfected Chinese hamster ovary (CHO) cells, LA-VIII was expressed at a 10-to 20-fold greater level compared with wildtype FVIII. The specific activity of purified LA-VIII was indistinguishable from wildtype recombinant FVlll and both exhibited similarthrombin activation coefficients. Wildtype recombinant-derived FVlll and LA-VIII also displayed similar timecourses of thrombin activation and heavy chain cleavage. However, compared with wildtype recombinant-derived FVIII, the light chain of LA-VIII was cleaved fivefold more rapidly by thrombin. Ad-ACTOR VI11 (FVIII) functions in the intrinsic pathway F of blood coagulation as the cofactor for the FIXa-mediated activation of FX.' Deficiency of FVIII results in the bleeding disorder, hemophilia A. In plasma, FVIII consists of a heterogeneous sized heavy chain polypeptide extending up to 200 Kd in a metal ion complex with an 80-Kd light chain polypeptide. This complex is stabilized through hydrophobic and hydrophilic interactions with von Willebrand factor (vWF). FVIII is processed from a single-chain polypeptide having the domain structure A 1 -A2-B-A3-C 1 -C2.2, 3 The heavy chain is composed of domains Al-A2-B while the light chain is composed of domains A3-Cl-C2. The large B domain is encoded by a single large exon4 and has no detectable homology to any other known genes. The B domain is extensively glycosylated on asparagine, serine, and threonine residues.536 In addition to the primary amino acid sequence, the isolation of the FVIII gene provided the ability to express FVIIl in transfected mammalian cells to study its biosynthesis and pro~essing.~ It was also possible to construct specific mutations within FVIII to study structural requirements for FVIII function.'-' Initial studies showed that deletion of the B domain resulted in a functional molecule as tested by in vitro assays and was expressed more efficiently compared with wildtype FVIII.7,10-'2 Hemophilia A is treated by frequent administration of FVIII preparations derived from pooled human plasma. In the past this therapeutic regimen had associated complications of blood-borne infectious pathogens. Recently, the availability of monoclonal antibody (MoAb) affinity-purified plasma FVIII preparations has significantly reduced risks associated with plasma-borne infectious agents.13 However, treatment is generally limited on demand basis because of the limited availability and high cost associated with highly purified plasma-derived FVIII. This may be alleviated in the near future by the availability of recombinantderived human FVIII. '4,'5 However, the present manufacturing process for FVIII has limitations because of the inefficiencies of producing, purifying, and characterizing this large heterogeneous dition of purified von Willebrand factor (vWF) did not alter the kinetics of thrombin cleavage or activation of either wildtype recombinant-derived FVlll or LA-VIII. The immunogenicity of LA-VIII was compared with wildtype FVlll in a novel model of neonatal tolerance induction in mice. The results did not detect any immunologic differences between wildtype FVlll and LA-VIII, suggesting that LA-VIII does not contain significant new epitopes that are absent in wildtype FVIII. LA-VIII was tolerated well on infusion into FVIII-deficient dogs and was able to correct the cuticle bleeding time similar to wildtype recombinant factor VIII. In vivo, LA-VIII was bound to canine vWF and exhibited a half-life similar to wildtype recombinant FVIII. These studies support that B-domain-deleted FVlll may be efficacious in treatment of hemophilia A in humans. glycoprotein. For these reasons it should be advantageous to produce a more efficiently expressed molecule that has reduced heterogeneity to reduce the cost to provide prophylactic therapy for hemophilia A. Here we describe the production and characterization of a B-domain-deleted form of FVIII and show that it has biochemical, immunologic, and in vivo functional properties very similar to wildtype recombinantderived human FVIII.
MATERIALS AND METHODS

Cell clone LA3-5 was obtained by cotransfection with dihydrofolate reductase (DHFR)
in the DHFR deficient cell line DUKX B11 l6 and selection for growth in the absence of nucleosides and increasing concentrations of methotrexate (MTX) up to 1 pmol/L as previously described.I2 The von Willebrand factor (vWF) expressing cell line PM5F was obtained by coamplification with an adenosine deaminase (ADA) gene and se-
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To obtain a cell line that expressed both LA-VI11 and vWF, a hybrid was generated by polyethylene glycol induced fusion of LA34 (grown in 1 pmol/L MTX) and PM5F (grown in 0.03 pmol/L dCF). The resulting hybrid was subsequently selected for growth in 0.03 pmol/ L dCF and 5 pmol/L MTX to yield clone G12. In addition, a clonal cell line expressing higher levels of LA-VIII, designated M18, was derived by coamplification of the LA-VI11 coding region contained within the PED expression vector'' by transfection of the vWF expressing cell line PM5F and selection for resistance to 1 pmol/L MTX and 0.1 pmol/L dCF. The wildtype FVIII and vWF coexpressing cell line C6 was previously described."
For analysis of FVIII and vWF expression, logarithmically growing cells were rinsed with phosphate-buffered saline (PBS) and fed either alpha medium (GIBCO Corp, Grand Island, NY) containing 10% dialyzed fetal calf serum (FCS) or serum-free a medium (medium supplemented with 5 g/L bovine serum albumin [BSA], 5 ng/mL selenium, 5 pg/mL insulin, 5 pg/mL transferrin, 0. I pg/mL putrescene, 0.01 pmol/L hydrocortisone, 2 mmol/L glutamine, and penicillin-streptomycin [GIBCO] ). After 24 and 48 hours the conditioned medium was harvested and centrifuged to remove cellular debris. At that time cell numbers were determined using a Coulter Counter (Hialeah, F'L). FVIII activity was assayed in achromogenic assay that measures the generation of FXa (Kabi Coatest; Kabi Vitrum, Stockholm, Sweden). Quantitation of vWF was performed by an enzymelinked immunoabsorbant assay (ELISA) using a goat anti-vWF antibody (American Diagnostica, Greenwich, CT) and normal pooled human plasma as a standard (George B. King Biomedical, St Louis, MO).
The synthesis of FVIII was monitored by metabolically labeling Chinese hamster ovary (CHO) cells expressing LA-VI11 (M 18 and G12) or wildtype FVIII (C6). The cells (growing on a 100-mmz dish) were rinsed and fed 1.5 mL of methionine-free minimal essential medium containing 10% dialyzed FCS, 20 pg/mL aprotinin (Sigma Chemical Co, St Louis, MO), 2 mmol/L glutamine, and penicillinstreptomycin. After 15 minutes at 37°C the medium was removed and the cells were fed 1.5 mL of methionine-free medium containing 300 pCi '?3-methionine (1,000 Ci/mmol/L; Amersham, Arlington Heights, IL). After 2 hours, the cells were fed 1.5 mL of complete a medium. Conditioned medium was harvested 4 hours later and processed as described. FVIII was immunoprecipitated with a heavychain-specific MoAb F8 coupled to CL-4B Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) and washed as described." Immunoprecipitates were resuspended in 50 mmol/L Tris-HC1 pH 7.5, 0.15 mmol/L NaCI, 2.5 mmol/L CaC12, and 5% glycerol and digested with 10 U/mL thrombin at 37°C for 1 hour. After thrombin digestion, samples were treated with Endoglycosidase-H or N-glycanase according to the manufacturer's specifications (Genzyme, Boston, MA). The polypeptides were separated on a sodium dodecyl sulfate (SDS) 8% low-bis polyacrylamide gel and exposed for autoradiography after treatment with En3hance (DuPont-New England Nuclear, Boston, MA).
Logarithmically growing cells were rinsed with PBS and fed serum-free medium. After 48 hours, conditioned medium was collected and FVIII purified by monoclonal affinity chromatography and ion exchange Mono-S and Mono-Q chromatography as previously described." For in vivo efficacy studies, the purification was performed with endotoxin-free reagents and the level of endotoxin in the final purified FVIII was less than 1.5 EU/I,O00 units.
The specific activity of FVIII was determined using the one-stage clotting assayz2 or the Kabi Coatest assay. One unit of FVIII is the amount of FVIII in I mL of pooled normal human plasma. Protein concentration was determined by BioRad (Richmond, CA). FVIIl at 10 pg/mL in 50 mmol/L Tns-HC1 pH 7.5, 0.15 mol/L NaCI, 2.5
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mmol/L CaC12, and 5% glycerol was incubated at room temperature with 0.5 pg/mL human thrombin. At short intervals aliquots were removed and clotting activity determined22 or fl-mercaptoethanol (2.5%) and SDS (1%) were added and samples heated at 85°C for 5 minutes. The polypeptides were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized by silver staining (BioRad). Band intensities were determined by scanning with an LKB UltroScan XL laser densitometer (Pharmacia LKB Biotechnology, Uppsala, Sweden). Where indicated, 30 pg/mL of human vWF (Diagnostica Stago, Asnieres-Sur-Seine, France) was added for 20 minutes at room temperature before thrombin treatment.
Recovery and survival studies and in vivo efficacy were performed in a hemophilic dog model as formed on each specimen as previously described?' Platelet counting was performed using an electronic particle counter as previously described.24 Fibrinogen assays were performed according to the methods of Clau~s.~' Functional activity in vivo was determined using the cuticle bleeding time (CBT) as previously described?4 CBTs were performed immediately before the infusion of the test material and then at 30 minutes and 2 hours postinfusion.
To investigate the interaction between the infused recombinant human FVIII and circulating canine vWF, selected plasma specimens were chromatographed on Sepharose 4B (Pharmacia Fine Chemicals) and FVIII antigen assays performed on eluting fractions to determine a shift in molecular weight of material demonstrating FVIII antigen?' The column was equilibrated in 0.15 mol/L NaCl, 0.025 mol/L sodium citrate (pH 6.5) and 1% (wt/vol) BSA (Sigma). After equilibration, the test samples were applied and eluted at a flow rate of 4.8 mL/h and 0.4-mL fractions collected and assayed for FVIII antigen and vWF antigen.
The animal studies described had received prior approval by the Queen's University Institutional Animal Care Committee, which operates in accordance with the guiding principles of the Canadian For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
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Induction of neonatal tolerance and measurement of antibody, Tolerogenic forms of plasma (pVIII)-or recombinantderived wildtype (rVIII) or Bdomain-deleted (LA-VIII) FVIII were prepared by adjusting the protein concentration to 500 pg/mL in PBS (9 mmol/ L sodium phosphate, 0.14 mol/L NaC1, pH 7.4), and centrifuging the resulting solutions at 20,OOOg for 15 minutes at 4°C to minimize protein aggregates. Immunogenic forms of these FVIII derivatives were prepared by emulsification of the tolerogenic forms in an immunologic adjuvant (RAS-Ribi Adjuvant system; Ribi Immunochemicals, Ogden, UT). Tolerogenic doses (50-pL volumes containing 25 pg FVIII) were administered intraperitoneally to neonatal Balb/ CBy mice (Jackson Laboratories, Bar Harbor, ME) within 30 hours of birth to induce a state of antigen-specific immunologic nonresponsiveness. Specificity of the induced nonresponsiveness was determined by monitoring the response to an unrelated protein antigen control (KLH: 5 pg keyhole limpet hemocyanin). Sham-tolerized animals received 50 pL protein-free PBS, and sham-immunized animals received control antigen, but no immunogenic doses of FVIII. All injections subsequent to the administration of the tolerogenic dose were administered subcutaneously, as emulsifications of protein in an immunologic adjuvant according to the schedule in Table 1 , section A.
The presence of rFV111-, LA-FVIII-, and KLH-specific antibodies in serum samples was assessed by a standard ELISA in which 96-well ELISA plates were coated with 100 pL test antigen solution (1 to 3 pg/mL) in carbonate buffer, pH 9.0. Nonspecific protein binding to the well surfaces was minimized by incubation with 300 p L 5% gelatin/PBS at 37°C for 30 minutes. Duplicate serial fivefold dilutions of test sera were added in 300-pL volumes, and the plates were incubated 18 hours at 4°C. Plates were washed four times with 1 mL/ well using PBS containing 0.5% Tween 20 (PBST). Specifically bound antibodies were detected using a 300 pL of a 1:1,000 dilution of horseradish peroxidase-conjugated goat anti-mouse Ig (heavy and light chain), and developed with o-phenylene diamine solution (5 mg/mL in carbonate buffer pH 9.0). The enzymatic reaction was halted by addition of 4.5 N H2S04, and absorbance at 490 nm was measured. Raw absorbance data was converted to percent maximal signal obtained for the sample, and evaluated by four parameter logistic analysis to provide titration values (dilution at which half-maximal response was observed).
FVIII-specific immunologic response was also monitored in all day 32 samples by Western immunoblot analysis directed against Tolerization and challenge were performed as described in Materials and Methods. After 24 days, mice were exsanguinated and sera taken for analysis. Section A: Timetable of tolerance induction for four groups of mice is shown. Section 6: The titer of specific lg reactive with wildtype FVlll 18 hours at room temperature. After this primary incubation step, the devices were disassembled, and the filters washed four times with PBST. The filters were then incubated for 2 hours at room temperature with rabbit anti-murine IgG, IgA, and IgM (heavy and light chain) diluted 1:1,000 in PBST, and washed four times with PBST. Signal was identified using 5 mmol/L MgCI2, 10 pmol/L ZnCI2, 50 mmol/ L 2-amino-2 methyl-1,3 propanedial pH 9.7 (Sigma). 0.2 mg/mL nitro blue tetrazolium (Sigma), and 0.2 mg/mL 5-bromo-4 chloro-3 indolyl phosphate (Sigma). (Fig 1 A) . However, for cell line G 12, and to a lesser extent M 18, this effect was attributable to a slower doubling time in the absence of serum because cellular productivity of LA-VI11 (LA-VIIl/cell) did not change with removal of serum (Fig 1 B) .
RESULTS
Characterization
The structure of polypeptides comprising LA-VI11 was studied by labeling cells expressing LA-VI11 or wildtype FVlll with %-methionine. Conditioned medium was harvested for analysis by immunoprecipitation and SDS-PAGE before and after digestion with thrombin alone or in combination with N-glycanase or endoglycosidase H (Fig 2) . FVlll isolated from G I2 and M I8 cells showed the same spectrum of polypeptides whether analyzed before or after thrombin digestion. The two primary species represented a douhlet ofthe heavy chain (0) and a doublet of the light chain (0). In addition, a small amount of single-chain LA-VI11 was detected (*). Pro-vWF and mature vWF that coprecipitated with LA-VI11 were also detected migrating at the top of the gel (arrows). In contrast, 
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with those of wildtype FVIII. In addition, wildtype FVIlI contained a heterogeneous smear at approximately 100 Kd representing the B domain, which was absent in LA-VIII. Digestion with N-glycanase and endoglycosidase H showed that LA-VI11 and wildtype VI11 exhibit the same mobility shifts for the light chain 73-Kd derived fragment and the 50-Kd heavy chain derived fragment (Fig 2, lanes 7 through 12) . No mobility shift was observed with the 43-Kd derived fragment, consistent with the absence of N-linked oligosaccharides on this p e~t i d e .~ These results show that the utilization and complexity of N-linked glycosylation sites in the 50-, 43-, and 73-Kd polypeptides are similar for LA-VI11 and wildtype recombinant FVIII.
LA-VI11 was purified by MoAb affinity chromatography as described in Materials and Methods. The specific activity of LA-VI11 was determined using an FXa generation assay and by the ability to clot FVIIIdeficient plasma. The values determined were well within the range obtained for wildtype recombinant human FVlIl ( a p proximately 3,000 U/mg by Coatest assay and 2,700 U/mg by clotting assay using FVIII-deficient plasma). Thrombin activation of LA-VI11 increased clotting activity approxiBiochemical anal.vsis of LA-VIII. (Fig 3A, lane I) , LA-VI11 was composed of three prominent species representing the 80-Kd light chain, a 92-Kd heavy chain, and a 170-Kd single chain (Fig 3A,  lane IO) . Upon thrombin digestion for increasing periods of time, the heavy chains of both LA-VI11 and wildtype FVIIl were cleaved at the same rate where maximal cleavage occurred after I minute. Densitometry ofthe thrombin cleavage products demonstrated similar kinetics of appearance of the 50-and 43-Kd heavy chain-derived polypeptides (Fig 3C) . In addition, the appearance and disappearance of a 90-Kd heavy chain intermediate was similar for both molecules ( Fig  3A) . The difference between the 92-Kd and 90-Kd heavy chain species for LA-VI11 is likely caused by the B-domainderived sequence (residue 741 to 1648) present on the 92-Kd species and absent on the 90-Kd thrombin cleaved species. The LA-VI11 light chain was 65% cleaved after I O seconds while wildtype recombinant FVIII required approximately I minute for 65% cleavage (Fig 3, A (Fig 3B, lanes 2 through 9) or LA-VI11 (Fig 3B, lanes 11 through 18) . Chromatography on CL4B Sepharose showed that both wildtype and LA-VI11 effectively bound vWF under these conditions (data not shown).
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and C). Addition of human
Because the rate of light chain cleavage of LA-VI11 was greater than wildtype recombinant FVIII, the thrombin activation of procoagulant activity was determined by a clotting assay using FVIII-deficient plasma. Both wildtype recombinant and LA-VI11 exhibited similar rapid activation of procoagulant activity with a peak after 1 minute, coincident with maximal cleavage of the heavy chain (Fig 3D) . In addition, both wildtype and LA-VI11 exhibited a similar rate of decay of procoagulant activity. Addition of vWF did not affect the rate of activation or inactivation of wildtype FVIII or LA-VI11 (data not shown).
A neonatal mouse tolerance model was used to evaluate the immunologic similarity of LA-VI11 and wildtype FVIII. This model takes advantage of the finding that administration of large quantities of a foreign antigen (tolerogen) to a newborn mouse renders the mouse specifically nonresponsive to that foreign antigen. The ability for a related antigen to induce an antibody response indicates that the immune system of the tolerized mouse recognizes distinct epitopes not present in the original tolerogen. Preliminary studies indicated that a single 25-pg dose of plasma-derived or recombinant-derived wildtype FVIII administered by intraperitoneal injection to neonatal Balb/CBy mice within 30 hours of birth resulted in the induction of a state of antigen-specific nonresponsiveness in 89% (48 of 54) treated animals. Mice tolerized to recombinant-derived FVIII were nonresponsive to subsequent challenge with recombinant-or plasma-derived FVIII. Similarly, mice tolerized with plasma-derived FVIII were nonresponsive on subsequent challenge with plasma-or recombinant-derived FVIII. Of 43 mice that received recombinant-derived FVIII challenge, only I responded with antitest antigen (a positive response is defined by titer > 100). Immunocompetence of experimental mice was scored by measuring the response to an unrelated immunogen, antigen KLH. All mice mounted significant response to this control immunogen, demonstrating full competence, and that any observed reduction in response to the test antigen was specific in nature. In contrast, all sham-tolerized mice mounted significant response to both the control antigen (KLH) and to test antigen (FVIII) (data not shown). These results support immunologic similarity of wildtype plasma-derived and recombinant-derived FVIII in the model system.
We then evaluated whether the tolerance developed to wildtype FVIII could be broken with a challenge of LA-VI11 using the protocol described Table 1 , section A. Newborn mice were either sham tolerized (groups A and B) or tolerized with wildtype recombinant VI11 (rVIII) (groups C and D) or LA-VI11 (group E). Ten days later the mice were challenged with either wildtype rVIII (groups A, D, and E) or LA-VI11 (groups B and C). The data in Table 1 , section B, show the amount of specific anti-FVIII Ig (IgG) detected by titration ELISA using either wildtype rVIII or LA-VIII. At day 16, 1 Immunologic characterization of LA-VIII. of 14 mice theoretically tolerized to rVIII showed borderline reactivity against both wildtype rVIII and LA-VI11 (from group C, Table 1 , section B). The antibody titers measured at day 32 were averaged both excluding and including the mouse showing significant anti-FVIII response (Table 1 , section B). At day 32, significant anti-FVIII antibody was detected in all sham-tolerized animals that were challenged with either rVIII or LA-VI11 (groups A and B). Significantly, 10-to 20-fold reduced titers were observed in mice that were tolerized with rVIII and challenged with rVIII or LA-VI11 (groups C and D). The nonresponsiveness to rVIII and LA-VI11 was specific because no difference in antibody response toward KLH was detected between the sham-tolerized and rVIII-or LA-VI11 tolerized mice. In contrast, mice that were tolerized to LA-VI11 and challenged with wildtype rVIII (group E) developed a significant anti-FVIII response after 32 days. The anti-FVIII antibodies in the LA-VI11 tolerized mice were reactive with LA-VI11 as well as wildtype rVIII. These results show that tolerance to wildtype rVIII could not be broken by either wildtype rVIII or LA-VI11 challenge. In contrast, tolerization to LA-VI11 could be broken by wildtype rVIII challenge.
To further characterize the response detected by ELISA, the day 32 murine sera were used to probe Western blots in which either wildtype FVIII or LA-VI11 were electrophoresed on an SDS-polyacrylamide gel and then transferred to nitrocellulose. The filters were probed with sera from the challenged mice as well as a rabbit anti-human FVIII polyclonal antibody (as positive control). The control anti-FVIII antibody showed strong reactivity with both wildtype and LA-VI11 FVIII whereas no reaction was detected with the 9 mice sera tested (data not shown), suggesting that the specificity of affinity of anti-FVIII response detected by ELISA in the serum was very low or that the antibody generated did not react by Western analysis. In conclusion, these experiments show that the mouse immune system could not detect any different epitopes between LA-VI11 and wildtype FVIII.
The in vivo efficacy of purified preparations wildtype FVIII and LA-VI11 were tested by infusion into two severely affected, congenitally FVIII-deficient animals as described.23 LA-VI11 was administered on day 1, followed by an identical study performed 2 days later with the wildtype FVIII. Blood samples were obtained pre-and post-FVIII infusion at various times. Coagulation testing performed on each sample included FVIII functional activity as measured in a one-stage clotting assay, fibrinogen levels, and a full blood count including platelets. Bleeding times were determined, after bleeding was induced in lightly anesthesized animals, by severing the apex of the nail cuticle using a guillotine device. The length of time for this induced bleeding to be arrested is the cuticle bleeding time (CBT). This stringent model for FVIII activity is based on the reproducible long bleeding time that occurs and for which cessation requires infusion of functional FVIILZ4 For both the wildtype and LA-VI11 FVIII, the infusion was tolerated without any observable side effects. In the first study, performed in a severely affected homozygous female, the FVIII activity and antigen survival curves for both preparations were very similar and in line with the anticipated t1/2 of 12 to 13 hours for
In vivo eficacy of LA-VIII.
For (Fig 4, A and B) . In the second study, performed in a severely affected male, very similar results were obtained with regard to the recovery and survival of functional FVIII activity for both preparations (data not shown). FVIII antigen levels were not measured in the second study. Plasma samples obtained in the first study 1 hour after infusion of both the wildtype and LA-VI11 were fractionated by Sepharose-4B chromatography and analyzed for the presence of FVIII and vWF antigen. Canine vWF antigen eluted between fractions 7 and 15 for animals that received either LA-VI11 or wildtype FVIII. Analysis of FVIII activity showed that both preparations had a significant and similar amount of FVIII antigen co-eluting with vWF, indicating that the vWF binding characteristics for wildtype FVIII and LA-VI11 were similar (Fig 4C) . CBTs were performed before and at 30 minutes and 2 hours (study I), and 30 minutes, 1 hour, and 2 hours (study 2) after the infusion of both preparations of FVIII. In each case, the cuticle bleeding time was corrected following the infusion of LA-VIII. The FVIII levels at the time of performing the CBTs in study 1 were 44% (30 minutes) and 40% (2 hours) of the normal canine plasma level. In the case of the second study, the levels were 146% (30 minutes), 136% (1 hour), and 127% (2 hours). In the case of the first study, the CBT was corrected 30 minutes after the infusion ofwildtype FVIII but not at 2 hours. The FVIII level at these times was 55% and 47%, respectively. In the second study, the CBTs were corrected at 30 minutes, 1 hour, and 2 hours after the infusion of wildtype FVIII when the levels were 106%, 92%, and 109%, respectively. Based on the stringent requirement for FVIII for correction of the CBT in this model system, the results show that LA-VI11 is functional in vivo.
DISCUSSION
The present study was undertaken to evaluate the biochemical, immunologic, and in vivo functional properties of a B-domain-deleted mutant of FVIII, designated LA-VIII. LA-VI11 was expressed at approximately IO-to 20-fold greater levels in CHO cells compared with wildtype FVIII when similar vectors, cells, and methods were used. The increased expression resulted from increased levels of LA-VI11 mRNA (data not shown) and increased secretion efficiency. The improved secretion efficiency correlated with reduced interaction with the glucose regulated protein of 78 Kd (GRP78 or BiP). 1227, 28 The expression levels attained, greater than 20 U/mL, were an order of magnitude greater than previous reports on B-domain-deleted FVIII.7.'0311 One posttranslational modification that may have become limiting for biosynthesis of functional FVIII at these high expression levels was sulfation of tyrosine. However, even at this high expression level we have previously shown that tyrosine sulfation was effi~ient.2~ Biochemically, LA-VI11 was similar to wildtype FVIII with respect to specific activity in clotting assays and FXa generation assays and also exhibited similar thrombin activation coefficients.
The single most significant difference between LA-VI11 and wildtype FVIII was that the light chain of LA-VI11 was more susceptible to thrombin cleavage. No difference was detected in the rate of heavy chain cleavage by thrombin. In addition, domain deletion (residues 797 through 1562) molecule was shown to exhibit increased sensitivity to thrombin activation compared with wildtype and those of Meulien et all' where a B-domain deletion (residues 77 1 through 1666) molecule was activated to a greater extent than wildtype FVIII. However, in both of these studies the rate of thrombin cleavage of the B-domain-deleted molecule was not compared with wildtype FVIII. Although it is likely that different deletions will exhibit slightly different properties, the properties of LA-VI11 described here closely resemble wildtype FVIII.
Previously, it was shown that vWF inhibited activity of Bothrops jararucussu venom activated porcine FVIII, presumably by binding to the intact FVIII light chain.30 It was proposed that cleavage of the FVIII light chain was required to release vWF and elicit FVIII procoagulant activity. In addition, vWF promoted thrombin cleavage of the FVIII light hai in.^' Therefore, we examined the effect of vWF on the cleavage and activation of human wildtype recombinant FVIII and LA-VIII. Addition of vWF did not affect either the procoagulant activity or the rate of light or heavy chain cleavage of either wildtype FVIII or LA-VIII. The difference between our results and those of Hill-Eubanks and Lollar may be attributed to the different species of FVIII being studied (human v porcine) and different assay systems (clotting assay and FXa generation assay).
Because of the increased susceptibility of the light chain to thrombin cleavage, we asked whether the molecule was safe and efficacious on infusion into a hemophilic dog. The results of two studies in two hemophilic dogs showed that the half-life of both antigen and activity of LA-VI11 was similar to wildtype recombinant FVIII. In vivo, LA-VI11 was also complexed with canine vWF to a similar degree as wildtype recombinant FVIII. In addition, LA-VI11 was well tolerated and did not affect any hematologic parameters studied, including fibrinogen levels or platelet counts. LA-VI11 was capable of correcting the CBT, approximately similar to wildtype recombinant FVIII. The results of these studies indicate that LA-VI11 is functional in this animal model.
A neonatal murine tolerance model was used to identify potential new or cryptic epitopes within LA-VIII. Administration of relatively large quantities of a foreign antigen to a newborn animal before the occurrence of 'self-nonself' discrimination events within the immature immune system can lead to a state of antigen-specific immunologic nonresponsiveness toward the foreign antigen.32*33 This response renders the animals specifically nonresponsive to the foreign antigen (tolerogen), which has been misidentified as a normal component of the protein repertoire of the tolerized animal. Specific nonresponsiveness to the tolerogen can be broken only by the administration of a similar, but distinct, antigen (xenoantigen) that shares many, but not all, epitopes present in the tolerogen. Response to these dissimilar epitopes on the challenge of xenoantigen results in the development of antibodies that may cross-react with the original tolerogen. If the animal develops no antibodies to the test antigen, the test antigen and the tolerogen may be considered immunologically identical.
These observations were used to design a neonatal murine model system of tolerance induction to evaluate immunologic equivalence of plasma-derived FVIII, wildtype recombinantderived FVIII, and LA-VIII. Control studies demonstrated that tolerance could be induced in almost 90% of mice by a single infusion of either recombinant-derived or plasma-derived FVIII into neonatal mice. Mice tolerized to plasmaderived FVIII also exhibited tolerance to recombinant-derived FVIII and vice versa. Thus, this analysis could not detect any immunologic differences between plasma-derived and recombinant-derived FVIII. Upon challenge with wildtype recombinant-derived FVIII, mice tolerized to LA-VI11 mounted a vigorous antibody response to both wildtype recombinant-derived FVIII and LA-VIII. The response to both immunogen and tolerogen is characteristic of termination of the tolerant ~t a t e .~' ,~~ In contrast, upon LA-VI11 challenge of mice tolerized to wildtype FVIII, only one of nine mice exhibited significant detectable antibodies that reacted with wildtype as well as LA-VIII. However, the antibody response could not be confirmed by Western immunoblot analysis, suggesting the antibodies generated may be of low affinity and/or titer to permit their detection by these procedures. We speculate that the response in the 1 of 9 mice was due to failure to tolerize the single responding mouse. The significant lack of response by the majority of the mice indicated that LA-VI11 is immunologically indistinguishable from wildtype FVIII. Previous immunologic characterization of another FVIII B-domain deletion molecule showed a specific immunologic response to the fusion junction peptide. In this case, the polyclonal antibody generated was characterized by immunoadsorption and cross-reactivity to peptides and wildtype FVIII.35 Our approach of neonatal tolerance induction should be more sensitive to identify any significant epitopes. Thus, we may have expected to obtain an antibody response to the fusion joint of the deletion molecule. However, LA-VI11 contains a potential N-linked glycosylation site at the fusion junction and may protect the protein from an antibody response. At present we do not know if the N-linked site is actually occupied with oligosaccharides. In addition to the ability to compare the immunologic properties of different derivatives of FVIII, the tolerance induction for FVIII in neonatal mice described here should provide a useful approach to derive mice that are tolerant to human FVIII for use as recipients for FVIII gene therapy to circumvent potential complications of antibody development to human proteins. 36 The results reported here suggest that B-domain-deleted FVIII (LA-VIII) is safe, efficacious, and immunologically similar to wildtype FVIII. To date a physiologically significant function cannot be attributed to the B domain. The particular advantages of B-domain-deleted FVIII for therapeutic use include its greater level of expression and significantly reduced heterogeneity. Thus, the cost for production should be significantly less than wildtype FVIII, thereby possibly permitFor personal use only. on November 16, 2017 . by guest www.bloodjournal.org From ting prophylactic treatment. Prophylactic use of FVIII may significantly reduce orthopedic ~omplications.~' In addition, the cDNA encoding B-domain-deleted FVIII is sufficiently small to allow incorporation into retroviral vectors for gene therapy. Previously it was shown that significant levels of LA-VI11 could be expressed using a retroviral vector." The results presented here suggest that B-domain-deleted FVIII may be efficacious for replacement therapy and/or gene therapy for hemophilia A.
